Very long-term outcomes after percutaneous coronary intervention with bare metal stents for unprotected left main

Akihiro Nomura1, Kyohei Yamaji, Shinichi Shirai

  • 1Division of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, Fukuoka. Japan. nomuryn@gmail.com

Insights

Bare metal stents (BMS) show feasibility for unprotected left main coronary artery disease (ULMCAD) up to 10 years. Left main trunk diameter and SYNTAX score predict outcomes after BMS PCI for ULMCAD.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Unprotected left main coronary artery disease (ULMCAD) poses significant risks.
  • Percutaneous coronary intervention (PCI) with bare metal stents (BMS) is a treatment option for ULMCAD.
  • Long-term outcomes of BMS for ULMCAD require further evaluation.

Purpose of the Study:

  • To assess very long-term clinical outcomes after PCI with BMS for ULMCAD.
  • To identify predictors of clinical outcomes in patients with ULMCAD treated with BMS.

Main Methods:

  • Retrospective analysis of 151 patients undergoing PCI with BMS for ULMCAD (March 1991-August 2001).
  • Median follow-up of 10.5 years.
  • Patient-oriented major adverse cardiac events (MACE) defined as all-cause death, myocardial infarction (MI), or coronary revascularization.

Main Results:

  • At 10 years, incidences were: cardiac death 11.1%, target lesion revascularization (TLR) 25.2%, and patient-oriented MACE 81.9%.
  • Pre-reference diameter of the left main trunk (LMT) was associated with TLR (aHR 0.28, p<0.001).
  • SYNTAX score independently predicted patient-oriented MACE (aHR 1.03, p=0.009).

Conclusions:

  • Left main trunk diameter and SYNTAX score are significant predictors of outcomes in ULMCAD treated with BMS.
  • BMS implantation for larger ULMCAD with lower SYNTAX scores is feasible with favorable outcomes up to 10 years.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...